First, any T cell subset converts to effector memory cells upon repetitive antigen engagement and amplification and in each stage of maturation requires appropriate costimulation to escape cell death; consequently, harnessing young T cells with a CD28-OX40 CAR will be beneficial and will rescue CCR7− cells when produced during an anti-tumor attack. The gene discussed is TNFRSF4; the disease is neoplasm.